Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell

Randal W Berg1, Peter J Ferguson, Mark D Vincent

  • 1Cancer Research Laboratories, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6.

Cancer Gene Therapy
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Canadian Perspectives Revisited: Consensus on the management of ALK-rearranged NSCLC.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Modern era systemic therapies: Expanding concepts of cure in early and locally advanced non-small cell lung cancer.

International journal of cancer·2024
Same author

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer.

Current oncology (Toronto, Ont.)·2023
Same author

Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trial.

BMC cancer·2022
Same author

The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial (QUINTETT): Randomized parallel clinical superiority trial.

Thoracic cancer·2022
Same author

Functional Lung Avoidance for Individualized Radiation Therapy: Results of a Double-Masked, Randomized Controlled Trial.

International journal of radiation oncology, biology, physics·2022
Same journal

Transcriptomic profiling of a novel gastric implantation model identifies mechanisms and pathways that drive implantation into explanted human peritoneum.

Cancer gene therapy·2026
Same journal

NCBP1 promotes the malignant progression of Wilms' tumor through stabilization of KPNA2 mRNA.

Cancer gene therapy·2026
Same journal

Reprogramming the tumor microenvironment via TFF3 targeting: a potential novel avenue to boost CAR-T cell therapy in solid tumors.

Cancer gene therapy·2026
Same journal

Hepatitis B virus-induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities.

Cancer gene therapy·2026
Same journal

Mesenchymal stem cell-mediated delivery boosts the efficacy of suicide gene therapy based on retroviral replicating vectors in peritoneally disseminated cancer.

Cancer gene therapy·2026
Same journal

The Tumor-suppressive role of CNTNAP2 in glioma: Dual regulation of the NDN-ERK axis and M2 macrophage polarization.

Cancer gene therapy·2026
See all related articles

Combining multiple antisense oligodeoxynucleotides (ODNs) targeting thymidylate synthase (TS) mRNA can enhance cancer cell proliferation inhibition. However, this combination does not improve sensitivity to TS-directed chemotherapy drugs.

Area of Science:

  • Molecular Biology
  • Anticancer Drug Development

Background:

  • Thymidylate synthase (TS) is crucial for DNA synthesis and cell proliferation, making it a key target in antitumor chemotherapy.
  • Antisense oligodeoxynucleotides (ODNs) have been developed to downregulate TS mRNA and protein levels, inhibiting cancer cell growth.

Purpose of the Study:

  • To investigate the synergistic or antagonistic interactions of using multiple ODNs targeting distinct, noncontiguous regions of TS mRNA.
  • To determine if combined ODN treatment enhances the efficacy of TS-directed chemotherapeutic drugs.

Main Methods:

  • Designing and applying multiple antisense ODNs targeting different regions of the TS mRNA.
  • Evaluating the effects of individual and combined ODN treatments on TS mRNA abundance, protein levels, and cancer cell proliferation.

Related Experiment Videos

  • Assessing the impact of combined ODN treatment on cancer cell sensitivity to raltitrexed and 5-fluorodeoxyuridine.

    • Main Results:

    • Certain combinations of TS antisense ODNs demonstrated superior reduction in TS mRNA and inhibition of cell proliferation compared to individual ODNs.
    • Combined ODN treatment did not further augment the enhanced sensitivity to anti-TS chemotherapeutic drugs observed with individual ODNs.

    Conclusions:

    • The combination of multiple antisense ODNs targeting distinct regions of TS mRNA can synergistically inhibit cancer cell proliferation.
    • The results suggest that TS mRNA or protein may have functions beyond thymidylate production that are targeted by antisense ODNs.
    • Using multiple antisense ODNs targeting different regions of the same mRNA is a promising strategy to enhance antisense therapy effectiveness.